Healthcare in the post-COVID era, where is Cell and Gene Therapy going?

Abstract

The post-COVID era has posed significant challenges to the pharmaceutical industry due to factors like raw material shortages from disrupted global supply chains, increased manufacturing needs and R&D costs, and regulatory changes such as the U.S. Inflation Reduction Act (IRA) affecting drug pricing and reimbursement. Additionally, the impending expiration of patents on blockbuster drugs, known as the “patent cliff,” has heightened the need for innovation.

We analyzed real-life data from publicly available databases (GlobalData) to understand how the healthcare sector has evolved, comparing different modalities and financing models (venture rounds, acquisitions, and IPOs) over a six-year period (2019 to 2024). The study highlights the dynamic nature of stakeholder interests and the need to understand both the shifts in trends since 2021 and the current factors driving more selective but larger capital investments in companies. Innovation is crucial for the pharmaceutical industry, with new modalities having a potentially greater impact.

Taking a closer look to Cell and Gene therapies (CGT), we surveyed academics, industry professionals, and investors to gain insights into perceived opportunities, challenges, and gaps. The survey revealed a positive outlook with increased confidence on maturity of the field and a call to further support development efforts.

We believe collaboration among stakeholders is vital at this turning point to support the growth of new modalities and ensure patient access to transformative medicines.

To read and download the full report please click here.